Olfactory deficits - An early cardinal sign of Parkinson's disease;Riechstörungen - Ein frühes kardinalsymptom des idiopathischen Parkinson-syndroms

Aktuelle Neurologie

Volumn 30, Issue 5, 2003, Pages 239-243

  Müller, Antje ^a   Abolmaali, N ^b   Hummel, T ^a   Reichmann, H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT;

CLINICAL FEATURE; CORRELATION ANALYSIS; CORTICOBASAL DEGENERATION; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; EVOKED RESPONSE; HUMAN; MOTOR PERFORMANCE; NEUROPHYSIOLOGY; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SMELLING DISORDER;

EID: 0038729648     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39966     Document Type: Review

References (41)

1. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chron Dis 1975; 28: 493-497
2. Doty RL, Deems D, Steller S. Olfactory dysfunction in Parkinson's disease: A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-1244
3. Hummel T, Sekinger B, Wolf SR et al. "Sniffin' sticks": olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997; 22: 39-52
4. Barz S, Hummel T, Pauli E et al. Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson's disease. Neurology 1997; 49: 1424-1431
5. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-287
6. Del Tredici K, Rub U, De Vos RA et al. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-426
7. Wenning GK, Shephard B, Hawkes C et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247-250
8. Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992; 32: 97-100
9. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson's disease a primary olfactory disorder? Qjm 1999; 92: 473-480
10. Polymeropoulos MH et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047
11. Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 1991; 11: 335-343
12. Daum RF, Sekinger B, Kobal G, Lang C. Riechprüfung mit "Sniffin' Sticks" zur klinischen Diagnostik des Morbus Parkinson. Nervenarzt 2000; 71: 643-650
13. Hüttenbrink KB. Riech- und Schmeckstörungen - Bewährtes und Neues zu Diagnostik und Therapie. Laryngo-Rhino-Otol 1997; 76: 506-514
14. Quint C, Temmel AF, Schickinger B et al. Patterns of non-conductive olfactory disorders in eastern Austria: a study of 120 patients from the Department of Otorhinolaryngology at the University of Vienna. Wien Klin Wochenschr 2001; 113: 52-57
15. Kobal G, Klimek L, Wolfensberger M et al. Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol 2000; 257: 205-211
16. Müller A, Mungersdorf M, Reichmann H et al. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521-524
17. Stern MB, Doty RL, Dotti M et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994; 44: 266-268
18. Müller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-811
19. Kobal G. Elektrophysiologische Untersuchungen des menschlichen Geruchssinns. Stuttgart: Thieme Verlag, 1981
20. Hummel T, Kobal G. Olfactory event-related potentials. In: Simon SA, Nicolelis MAL (eds): Methods and Frontiers in Chemosensory Research. Boca Raton, Florida USA: CRC press, 2001: 429-464
21. Hummel T, Pietsch H, Kobal G. Kallmann's syndrome and chemosensory evoked potentials. Eur Arch Otorhinolaryngol 1991; 248: 311-312
22. Kobal G, Hummel T. Olfactory and intranasal trigeminal event-related potentials in anosmic patients. Laryngoscope 1998; 108: 1033-1035
23. Doty RL, Brugger WPE, Jurs PC et al. Intranasal trigeminal stimulation from odorous volatiles: psychometric responses from anosmic and normal humans. Physiol Behav 1978; 20: 175-185
24. Kobal G, Hummel T, Pauli E. Correlates of hedonic estimates in the olfactory evoked potential. Chemical Senses 1989; 14: 718
25. Kettenmann B, Hummel C, Stefan H, Kobal G. Multiple olfactory activity in the human neocortex identified by magnetic source imaging. Chemical Senses 1997; 22: 493-502
26. Hummel T, Pauli E, Stefan H et al. Chemosensory event-related potentials in patients with temporal lobe epilepsy. Epilepsia 1995; 36: 79-85
27. Kobal G, Hummel C. Cerebral chemosensory evoked potentials elicited by chemical stimulation of the human olfactory and respiratory nasal mucosa. Electroenceph Clin Neurophysiol 1988; 71: 241-250
28. Livermore A, Hummel T, Kobal G. Chemosensory event-related potentials in the investigation of interactions between the olfactory and the somatosensory (trigeminal) systems. Electroencephalogr Clin Neurophysiol 1992; 83: 201-210
29. Pause BM, Krauel K. Chemosensory event-related potentials (CSERP) as a key to the psychology of odors. Int J Psychophysiol 2000; 36: 105-122
30. Abolmaali ND, Hietschold V, Vogl TJ et al. MR evaluation in patients with isolated anosmia since birth or early childhood. Am J Neuroradiol 2002; 23: 157-164
31. Yousem DM, Geckle RJ, Bilker WB, Doty RL. Olfactory bulb and tract and temporal lobe volumes. Normative data across decades. Ann N Y Acad Sci 1998; 855: 546-555
32. Berendse HW, Booij J, Francot CM et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001; 50: 34-41
33. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-576
34. Koutssilieri E, Chen TS, Rausch WD, Riederer P. Selegeline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenypyridinium. Eur J Pharmacol 1996; 303: 181-186
35. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)-aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm 1998; 52 (Suppl): 287-300
36. The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996; 40: 99-107
37. Gille G, Rausch WD, Hung ST et al. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 2002; 109: 633-643
38. Gille G, Rausch WD, Hung ST et al. Protection of dopaminergic neurons in primary culture by lisuride. J Neural Transm 2002; 109: 157-169
39. Gerlach M, Reichmann H, Riederer P. Noch in experimenteller Erprobung befindliche, zukünftige Therapien der Parkinson-Krankheit: Ausblick. In: Gerlach M, Reichmann H, Riederer P (Hrsg): Die Parkinson-Krankheit. Grundlagen, Klinik, Therapie. Wien, New York: Springer, 2001: 210-216
40. Koller WC et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991; 41: 8-13
41. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-446